Autopsy report · NCT00923234

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

“The primary objective has already been answered with the number of recruited patients.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Technische Universität Dresden

Sponsor type

University, hospital or other

Conditions

Myelodysplastic Syndromes; Acute Myelogenous Leukemia

Interventions

Azacitidine; Lenalidomide

Sites

4

Countries

Germany

Trials that died the same way

• Novel Interventions in HIV-1 Infection
  “Data from the 12 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives.” (79% match in meaning)
• TuLip : Role of the Tumor Environment in Cancer-related Fat Loss
  “Limited number of recruited patients” (78% match in meaning)
• Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients
  “small number of patients got recruited” (78% match in meaning)
• An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study
  “Enrolled requested number of patients and completed study. In analysis” (66% match in meaning)
• Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics
  “Number of included patients is sufficient.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.